Evonik to build new drug-product manufacturing facility in Vancouver

This article was originally posted on Chemical Engineering.

Evonik Industries AG (Essen, Germany) is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The facility will increase Evonik’s development and manufacturing capacity, helping pharmaceutical and biotech customers bring lipid-based pharmaceutical products including vaccines, therapeutics, and other advanced medicines from development through commercial scale. Evonik’s total investment […]

The post Evonik to build new drug-product manufacturing facility in Vancouver appeared first on Chemical Engineering.

Evonik to build new drug-product manufacturing facility in Vancouver

Related Conversations

Evonik to sell select pharmaceutical ingredients assets in Hanau

Evonik investing $100 million to expand API production site in Indiana

Evonik expands global production of hydroxyl‑terminated polybutadienes

Evonik develops methanol optimization measures for methionine production

Evonik partners with University of Guanajuato, Mexico, to advance sustainable mining chemistry

Recent Conversations

Robots in substations: value only if they see what SCADA cannot

Selling the Boring Fix: Pricing Reliability Upgrades

Automating Substation Ops: Where It Helps and Where It Hurts

Leadership by 15 Minute Fixes

Closed-loop drumming: safer, cleaner, but watch the bottlenecks

Your Conversations

Envalior and SECARA to develop circular PA6 pathway from end-of-life vehicle plastics

Emvolon and Freepoint Commodities announce partnership to scale biomethanol production from waste gases globally

Solstice Advanced Materials and Element Solutions mutually terminate merger agreement

Cyclic Materials to expand rare-earth recycling infrastructure in South Carolina and Arizona

Evonik to build new drug-product manufacturing facility in Vancouver